Alnylam Pharmaceuticals ALNY Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.71B+3.2% | $1.66B+11.1% | $1.49B+33.8% | $1.12B+9.2% | $1.02B+5.5% | ||
| $1.3B+3.8% | $1.25B+1.4% | $1.23B-29.2% | $1.74B+8.6% | $1.61B-6.7% | ||
| —— | —— | —— | —— | —— | ||
| $883.96M+13.7% | $777.57M-19.4% | $964.77M+70.1% | $567.11M+35.7% | $418.04M+3.1% | ||
| $84.03M+1.6% | $82.72M+9.7% | $75.38M+5.2% | $71.69M+9.3% | $65.58M-16.5% | ||
| $11.69M-17.6% | $14.18M-36.3% | $22.25M-2.7% | $22.87M-2.3% | $23.4M-2.4% | ||
| $65.46M+0.5% | $65.12M+83.4% | $35.5M-18.9% | $43.78M-18.9% | $53.99M-16.9% | ||
| $38.98M+20.5% | $32.34M-16.8% | $38.85M+15.1% | $33.75M+2.4% | $32.96M+24.7% | ||
| $242.1M-14.1% | $281.89M+49.9% | $188.04M+27.6% | $147.31M-3.3% | $152.42M+30.3% | ||
| $4.22B+4.2% | $4.05B+2.5% | $3.95B+8.5% | $3.64B+11.5% | $3.27B-0.8% | ||
| $518.26M+1.0% | $513.15M+2.3% | $501.75M+0.4% | $499.79M+0.2% | $498.68M-0.8% | ||
| $189.3M-2.9% | $194.92M+1.8% | $191.39M-0.5% | $192.4M-2.4% | $197.23M+3.2% | ||
| $63.55M+6.9% | $59.46M+6.5% | $55.84M-2.3% | $57.17M-22.6% | $73.82M+13.0% | ||
| $5.13B+3.3% | $4.97B+2.4% | $4.85B+6.3% | $4.57B+8.4% | $4.21B-0.6% | ||
| $946.49M-12.4% | $1.08B-6.4% | $1.15B+25.5% | $918.97M+30.5% | $704.17M-11.3% | ||
| $3.21M-33.7% | $4.85M+90.7% | $2.54M-83.1% | $15.08M-46.4% | $28.16M-49.2% | ||
| $45.66M+0.3% | $45.52M+1.7% | $44.76M-2.9% | $46.1M+0.2% | $46.01M+9.8% | ||
| $1.35B-8.0% | $1.47B-5.7% | $1.56B+19.6% | $1.3B+20.9% | $1.08B-9.3% | ||
| $218.03M-3.1% | $225.09M+0.7% | $223.42M-0.5% | $224.45M-2.4% | $230.06M+0.2% | ||
| $7.61M+0.2% | $7.59M-22.3% | $9.77M-10.6% | $10.93M+86.2% | $5.87M+18.2% | ||
| $4.05B-2.9% | $4.18B-9.5% | $4.62B+7.0% | $4.32B+5.3% | $4.1B-1.8% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| 250M0.0% | 250M0.0% | 250M0.0% | 250M0.0% | 250M+19,235% | ||
| $7.6B+1.1% | $7.51B+1.3% | $7.41B-3.6% | $7.69B+2.6% | $7.5B+1.5% | ||
| -$6.5B+3.1% | -$6.7B+6.4% | -$7.16B+3.4% | -$7.41B-0.9% | -$7.35B-0.8% | ||
| -$24.89M-23.9% | -$20.1M+7.7% | -$21.78M+27.3% | -$29.95M+20.2% | -$37.52M-8.7% | ||
| $1.08B+36.3% | $789.18M+237% | $233.89M-6.7% | $250.59M-41.2% | $426.14M+535% | ||
| $5.13B+3.3% | $4.97B+2.4% | $4.85B+6.3% | $4.57B+8.4% | $4.21B-0.6% | ||
| $1.3B+3.8% | $1.25B+1.4% | $1.23B-29.2% | $1.74B+8.6% | $1.61B-6.7% | ||
| $63.55M+6.9% | $59.46M+6.5% | $55.84M-2.3% | $57.17M-22.6% | $73.82M+13.0% | ||
| $189.3M-2.9% | $194.92M+1.8% | $191.39M-0.5% | $192.4M-2.4% | $197.23M+3.2% | ||
| $116.96M-7.2% | $125.98M+27.8% | $98.56M— | —— | —— | ||
| $189.3M-2.9% | $194.92M+1.8% | $191.39M-0.5% | $192.4M-2.4% | $197.23M+3.2% | ||
| $63.55M+6.9% | $59.46M+6.5% | $55.84M-2.3% | $57.17M-22.6% | $73.82M+13.0% | ||
| $189.3M-2.9% | $194.92M+1.8% | $191.39M-0.5% | $192.4M-2.4% | $197.23M+3.2% | ||
| $63.55M+6.9% | $59.46M+6.5% | $55.84M-2.3% | $57.17M-22.6% | $73.82M+13.0% | ||
| —— | —— | —— | —— | —— | ||
| $946.49M-12.4% | $1.08B-6.4% | $1.15B+25.5% | $918.97M+30.5% | $704.17M-11.3% | ||
| $946.49M-12.4% | $1.08B-6.4% | $1.15B+25.5% | $918.97M+30.5% | $704.17M-11.3% | ||
| —— | —— | —— | —— | —— | ||
| $1.01B+0.2% | $1.01B-3.1% | $1.04B+1.3% | $1.03B+0.1% | $1.03B+0.1% | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| 133.4M+0.8% | 132.4M+0.4% | 131.8M+0.6% | 131M+0.5% | 130.3M+0.8% | ||
| 5M0.0% | 5M0.0% | 5M0.0% | 5M0.0% | 5M0.0% | ||
| 0— | 0— | 0— | 0— | 0— | ||
| 0— | 0— | 0— | 0— | 0— | ||
| $7.6B+1.1% | $7.51B+1.3% | $7.41B-3.6% | $7.69B+2.6% | $7.5B+1.5% | ||
| $1.33M+0.8% | $1.32M+0.5% | $1.32M+0.6% | $1.31M+0.5% | $1.3M+0.8% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| $250M0.0% | $250M0.0% | $250M0.0% | $250M0.0% | $250M0.0% | ||
| $133.44M+0.8% | $132.38M+0.4% | $131.79M+0.6% | $130.98M+0.5% | $130.31M+0.8% | ||
| $133.44M+0.8% | $132.38M+0.4% | $131.79M+0.6% | $130.98M+0.5% | $130.31M+0.8% | ||
| $1.01B+0.2% | $1.01B-3.1% | $1.04B+1.3% | $1.03B+0.1% | $1.03B+0.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $116.12M+4.0% | $111.64M+15.6% | $96.61M-3.8% | $100.4M-9.0% | $110.35M-4.4% | ||
| $11.69M-17.6% | $14.18M-36.3% | $22.25M-2.7% | $22.87M-2.3% | $23.4M-2.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| $5M0.0% | $5M0.0% | $5M0.0% | $5M0.0% | $5M0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $22.17M0.0% | $22.17M-56.8% | $51.31M-25.2% | $68.59M0.0% | $68.59M0.0% | ||
| —— | —— | —— | —— | —— | ||
| $477.04M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Alnylam Pharmaceuticals's total assets?
- Alnylam Pharmaceuticals (ALNY) holds $5.1B in total assets, up 21.7% year over year.
- How much debt does Alnylam Pharmaceuticals have?
- Alnylam Pharmaceuticals carries $263.7M in total debt against $1.1B of shareholders' equity, a debt-to-equity ratio of 0.25.
- How much cash does Alnylam Pharmaceuticals have?
- Alnylam Pharmaceuticals holds $1.7B in cash and equivalents.
- Can Alnylam Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.13 — current assets exceed current liabilities.
- Where does Alnylam Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
